Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
A goal of early-phase clinical trials is to discover a drug's possible side effects. But there is significant variation in how drug side effects are reported.
Some solid tumors have a very high growth rate, which often leads to a lack of vascularization due to the impossibility to develop, at the same time, the blood vessels that accompany and nourish it.
Researchers have discovered a pathway that regulates special immune system cells in lung cancer tumors, suppressing them and allowing tumors to grow.
Thanks to CRISPR-based genetic screens, researchers were able to detect genes that play a major role in lung cancer metastasis, cancer immunotherapy, sickle-cell anemia, and a host of other medical disorders.
A team of scientists has discovered that the WDR74 protein plays a vital role in metastasis progression in lung cancer and melanoma primary tumors.
In a genome-wide CRISPR-Cas9 screen published in Nature Immunology in January 2020, a group of researchers described a potential universal target on cancer cells.
A team of scientists has recently outlined the need to develop and standardize lipidomic measurements and baseline figures.
A recent study has revealed that the expression of long noncoding RNA LINC00426 is related to prognosis for non‐small cell lung cancer.